Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a new RNA virus that
is homologous with the previously known SARS‐CoV‐2 and Middle East respiratory syndrome
(MERS) coronaviruses. SARS‐CoV‐2 binds to various cell types, including lung epithelial
cells, via the angiotensin‐converting enzyme (ACE)‐2 molecules expressed on the cell
surface. After binding, viral RNA enters the cytosol of the infected cells and stimulates
intracellular signals to activate intranuclear gene transcriptions of multiple pro‐inflammatory
cytokines, including tumor necrosis factor alpha, interleukin (IL)‐6, and IL‐1, causing
substantial inflammatory reactions.
1
,
2
In susceptible patients, the complex inflammatory responses, the so‐called cytokine
storm, would lead to severe acute respiratory distress syndrome.
2
SARS‐CoV‐2 infection triggers autoimmunity aside from inflammation. The clinical features
of the coronavirus disease 2019 (COVID‐19) may include ground‐glass opacity on chest
radiography, coagulopathy, and other hematological abnormalities that resemble those
found in autoimmune diseases.
3
,
4
Autoantibodies, including anti‐nuclear, anti‐Sjögren’s syndrome (SS)‐A/Ro, anti‐neutrophilic
cytoplasmic, anti‐cyclic peptide containing citrulline, and anti‐interferon were detected
in COVID‐19 patients.
5
,
6
,
7
As for T cell immunity, long‐term antigenic stimulation by SARS‐CoV2 would induce
T cell activation and exhaustion in both CD4+ and CD8+ T cells.
8
,
9
Furthermore, a T‐helper 17 (Th17) phenotype has been shown in COVID‐19, as the T cells
of patients with COVID‐19 produce more IL‐17 than those of controls.
9
T cell exhaustion and Th17 phenotype are characteristics found in autoimmune rheumatic
diseases, such as in systemic lupus erythematosus (SLE).
10
In fact, a considerable number of COVID‐19 patients were diagnosed as having autoimmune
rheumatic diseases as they fulfilled the respective criteria.
4
,
11
,
12
In general, infection, either viral or bacterial, is recognized as the most critical
factor to accelerate the incidence and/or disease activity of autoimmune diseases.
For example, parvovirus, hepatitis virus, and Epstein‐Barr virus (EBV) have been significant
candidates as pathogens in autoimmune diseases such as SLE and SS.
13
,
14
The precise mechanisms by which infection would accelerates autoimmunity are unclear;
however, it may be plausible that infection evokes antiviral or antibacterial immune
responses and activates inflammatory cytokines, which lead to a dysregulation of innate
and adaptive immunity. Pusch et al
15
described that viruses induce “heterologous immunity” to the infected host, altering
adaptive immune responses to viral and self‐antigens. Moreover, EBV evokes B lymphocyte
activation associated with overproduction of autoantibodies.
16
A “molecular mimicry” may exist between the viral antigen and autoantigen(s).
17
,
18
Coxsackie virus, for example, has sequence homologies between the viral protein and
an autoantigen, Ro60 peptide, which is often found in SS and other autoimmune diseases.
12
In addition, infections themselves, or the administration of anti‐pathogenic agents,
may alter the host's intestinal homeostasis, causing dysbiosis in the gut flora. Recent
investigations suggest that the alteration of gut homeostasis, or dysbiosis, is crucial
in the induction of autoimmune diseases.
19
For instance, the potential role of a species of Gram negative bacteria in oral and
gut microbiota, that is, Prevotella spp., in the pathogenesis of rheumatoid arthritis
is attracting widespread interest.
19
,
20
As for SS, researchers have suggested an association between gut dysbiosis and the
severity of dry eye.
21
Of note, in 2011, Shoenfeld et al
22
identified the concept of ASIA syndrome (autoimmune/inflammatory syndrome induced
by adjuvants). The proposed syndrome encompasses a broad spectrum of autoimmunity
that is induced after exposure to external factors such as infections.
22
Considering the time gap between exposure to an infection and autoimmune disease diagnosis,
the authors hypothesized that "the non‐antigenic activation” of immunity might determine
the degree of autoimmune reaction after the infection. In the proposed entities for
the diagnosis of “ASIA,” “exposure to external stimuli” is one of the major criteria.
According to the concept, SS is a typical example of “ASIA”.
23
Considering these findings, the current pandemic of COVID‐19 would evoke the occurrence
of autoimmune rheumatic diseases such as SLE or SS,
24
which may constitute the ASIA syndrome.
12
To support this notion, it was observed that a significant number of patients with
COVID‐19 show clinical and laboratory findings similar to those in autoimmune rheumatic
diseases.
24
The sequence homology between SARS‐CoV‐2 spike and nuclear proteins and human peptides
has been demonstrated.
17
,
18
Moreover, altered gut dysbiosis after SARS‐CoV‐2 infection has been reported,
25
suggesting its implication in dysregulated immunity in COVID‐19.
Regarding other coronaviruses, only few reports have described the occurrence of autoimmune
diseases after SARS‐CoV or MERS‐CoV infection, owing to the relatively small‐scale
pandemic compared with the current COVID‐19 pandemic. However, MERS‐CoV was reported
to induce pro‐inflammatory reactions and Th17 cytokine profile,
26
suggesting a possibility that it triggers autoimmunity.
Brito‐Zerón et al
27
reported that patients who developed primary SS after contracting SARS‐COV‐2 infection
manifested clinical presentation similar to those in the general population. Nevertheless,
Fernandez‐Gutierrez et al
28
demonstrated a slight but significant difference in the crude incidence of COVID‐19‐related
hospital admission among different rheumatologic diseases, with SS being one of the
conditions with a higher risk. This finding may support the implication of viral infection
in the pathophysiology of SS.
Therefore, I propose that autoimmunity against the salivary glands should be carefully
monitored, as SARS‐CoV‐2 infects human salivary glands as abundantly so that the saliva
could be used as an excellent clinical sample for COVID‐19 diagnosis.
29
The expression of ACE2, the SARS‐CoV‐2 receptor, was even higher in minor salivary
glands than in the lungs.
30
After the infection, saliva may cultivate the live virus, and the salivary glands
would act as a long‐term viral reservoir of SARS‐CoV‐2.
30
Hence, autoimmune sialoadenitis, which is or at least mimics SS, might become apparent
even after susceptible individuals recover from COVID‐19 (Figure 1). The well‐known
complaint of altered taste and smell functions in patients with COVID‐19
31
may reflect in a part a clinical manifestation of salivary dysfunction.
FIGURE 1
Severe acute respiratory syndrome coronavirus 2 infection with potential of developing
Sjögren’s syndrome
Conversely, because of the mimicry between viral spike protein and human cells, whether
the messenger RNA (mRNA)‐based anti‐SARS‐CoV‐2 vaccines might stimulate an unwanted
immune reaction in individuals with immune dysfunctions is controversial.
32
The speculation may not be limited to mRNA vaccines, as an association between specific
vaccination (eg, influenza vaccine) and SS or the production of anti‐Ro/anti‐La antibodies
has been reported.
23
Thus, the infection and/or vaccination might trigger or accelerate autoimmune responses
against the spike protein of the SARS‐CoV‐2 in genetically susceptible individuals
or patients with immune dysfunction. In this concern, not only autoimmune rheumatic
diseases but also other autoimmunity entities such as hepatitis
33
and thyroiditis
34
have been reported to emerge after vaccination against SARS‐CoV‐2. Therefore, the
potential stimulatory effect of SARS‐CoV‐2 vaccines (regardless of mRNA, virus vectored,
or protein subunit) to brake immunological tolerance should be examined for both short‐
and long‐term events. Nevertheless, considering the severe outcome of COVID‐19, vaccinations
should be processed under a balance between the risk and the benefit for each individual
in this pandemic.
32
CONFLICT OF INTEREST
None.